Dimensional Fund Advisors LP Purchases 120,207 Shares of Charles River Laboratories International, Inc. $CRL

Key Points

• Dimensional Fund Advisors LP raised its stake in Charles River by 11.9%, buying 120,207 shares to hold 1,130,905 shares (about 2.30% of the company) valued at roughly $176.9 million.
• Quarterly results and guidance: Charles River beat EPS estimates with $2.39 vs. $2.33 and reported $994.2M in revenue, but a negative net margin; it set FY2026 EPS guidance of 10.70–11.20 while analysts model 9.36 EPS and the consensus price target is $203.57 (Moderate Buy).
• Market snapshot: Shares traded around $175 (down 3.4%), market cap about $8.62B, 52-week range $91.86–$228.88, and institutional investors own 98.91% of the stock.

Dimensional Fund Advisors LP grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 11.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,130,905 shares of the medical research company's stock after buying an additional 120,207 shares during the quarter. Dimensional Fund Advisors LP owned 2.30% of Charles River Laboratories International worth $176,909,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Jones Financial Companies Lllp raised its holdings in Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company's stock worth $253,000 after acquiring an additional 1,074 shares during the last quarter. Empowered Funds LLC purchased a new stake in Charles River Laboratories International during the 1st quarter valued at $418,000. Bank of New York Mellon Corp increased its holdings in shares of Charles River Laboratories International by 11.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 386,049 shares of the medical research company's stock worth $58,575,000 after purchasing an additional 40,720 shares in the last quarter. Huntington National Bank increased its holdings in shares of Charles River Laboratories International by 126.8% in the 2nd quarter. Huntington National Bank now owns 676 shares of the medical research company's stock worth $103,000 after purchasing an additional 378 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in shares of Charles River Laboratories International in the second quarter worth $400,000. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Down 3.4%

Charles River Laboratories International stock opened at $175.08 on Monday. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88. The company has a market cap of $8.62 billion, a P/E ratio of -59.15, a P/E/G ratio of 2.98 and a beta of 1.64. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. The business has a 50-day simple moving average of $195.31 and a two-hundred day simple moving average of $181.03.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. During the same quarter last year, the firm posted $2.66 earnings per share. The firm's revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on CRL. JPMorgan Chase & Co. increased their price objective on Charles River Laboratories International from $165.00 to $190.00 and gave the company a "neutral" rating in a research report on Monday, December 15th. UBS Group boosted their target price on Charles River Laboratories International from $170.00 to $175.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 25th. Morgan Stanley set a $185.00 target price on shares of Charles River Laboratories International in a research note on Monday, December 1st. Barclays dropped their price target on shares of Charles River Laboratories International from $215.00 to $200.00 and set an "overweight" rating on the stock in a report on Thursday, February 19th. Finally, Citigroup lifted their price target on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a "buy" rating in a research note on Friday, January 16th. Ten research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $203.57.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.